Vimarsana
Biggest News Aggregation in the World

Page 2 - Eric Schoen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eric Schoen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eric Schoen Today - Breaking & Trending Today

Cassava Sciences Completes Dividend Distribution of - Vimarsana News

Cassava Sciences Completes Dividend Distribution of

Shareholders of Record Received Warrants to Purchase Shares of Common Stock Warrants Trade on Nasdaq Under the Ticker “SAVAW”Warrant Holders Who Choose to...

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders - Vimarsana News

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders

Shareholders of Record Received Warrants to Purchase Shares of Common Stock Warrants Trade on Nasdaq Under the Ticker “SAVAW”Warrant Holders Who Choose to Exercise During an Early Period Will...

Cassava Sciences Appoints Three New Members to its Board of Directors - Vimarsana News

Cassava Sciences Appoints Three New Members to its Board of Directors

Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. GovernmentAUSTIN, Texas, Dec. 07, 2023 -- Cassava Sciences, Inc. , a...

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results - Vimarsana News

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected...

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results - Vimarsana News

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

07.11.2023 - Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected approximately year-end 2024; top-line results for 76-week ...